Directed Therapies in Lung Cancer: New Hope?

被引：3
|
作者：
Parente Lamelas, Isaura [1 ]
Abal Arca, Jose [1 ]
Firvida Perez, Jose Luis [2 ]
机构：
[1] Complexo Hosp Univ Ourense, Serv Neumol, Orense, Spain
[2] Complexo Hosp Univ Ourense, Med Oncol Serv, Orense, Spain
来源：
ARCHIVOS DE BRONCONEUMOLOGIA | 2012年 / 48卷 / 10期
关键词：
Lung cancer; Epidermal growth factor receptor; Vascular endothelial growth factor; Anaplastic lymphoma kinase; Erlotinib; Gefitinib; Bevacizumab; Crizotinib; GROWTH-FACTOR-RECEPTOR; EML4-ALK FUSION GENE; PHASE-III; OPEN-LABEL; 1ST-LINE THERAPY; GEFITINIB; MUTATIONS; SURVIVAL; ERLOTINIB; CHEMOTHERAPY;
D O I：
10.1016/j.arbres.2012.03.007
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Lung cancer (LC) is a serious health problem due to its high incidence and mortality. Surgery is the most effective therapeutic strategy in this type of tumor, but in recent years new drugs are being investigated that target specific components of the tumor cells, improving survival in patients with advanced disease and relapse. We present a review of individualized treatments in LC, particularly therapies that inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and anaplastic lymphoma kinase (ALK). (c) 2011 SEPAR. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码：367 / 371
页数：5
相关论文
共 50 条
  • [21] Epidermal Growth Factor Receptor-Mutant Lung Cancer New Drugs, New Resistance Mechanisms, and Future Treatment Options
    Piotrowska, Zofia
    Sequist, Lecia V.
    CANCER JOURNAL, 2015, 21 (05) : 371 - 377
  • [22] Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned
    Belluomini, Lorenzo
    Riva, Silvia Teresa
    Simbolo, Michele
    Nocini, Riccardo
    Trestini, Ilaria
    Avancini, Alice
    Tregnago, Daniela
    Ferrara, Miriam Grazia
    Caldart, Alberto
    Dodi, Alessandra
    Calio, Anna
    Bria, Emilio
    Scarpa, Aldo
    Milella, Michele
    Menis, Jessica
    Pilotto, Sara
    CELLS, 2021, 10 (10)
  • [23] Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies
    Li, Tianhong
    Kung, Hsing-Jien
    Mack, Philip C.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) : 1039 - 1049
  • [24] Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience
    Hotta, Katsuyuki
    Kiura, Katsuyuki
    Takigawa, Nagio
    Suzuki, Etsuji
    Yoshioka, Hiroshige
    Okada, Toshiaki
    Kishino, Daizo
    Ueoka, Hiroshi
    Inoue, Koji
    Tabata, Masahiro
    Tanimoto, Mitsune
    LUNG CANCER, 2010, 70 (03) : 308 - 312
  • [25] EGFR Mutations in Non-Small-Cell Lung Cancer Find, Divide, and Conquer
    Morgensztern, Daniel
    Politi, Katerina
    Herbst, Roy S.
    JAMA ONCOLOGY, 2015, 1 (02) : 146 - 148
  • [26] The Introduction of Systematic Genomic Testing for Patients with Non-Small-Cell Lung Cancer
    Cardarella, Stephanie
    Ortiz, Taylor M.
    Joshi, Victoria A.
    Butaney, Mohit
    Jackman, David M.
    Kwiatkowski, David J.
    Yeap, Beow Y.
    Jaenne, Pasi A.
    Lindeman, Neal I.
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (12) : 1767 - 1774
  • [27] Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 44 - 54
  • [28] Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience
    Kudo, Kenichiro
    Hotta, Katsuyuki
    Bessho, Akihiro
    Nogami, Naoyuki
    Kozuki, Toshiyuki
    Kuyama, Shoichi
    Inoue, Koji
    Harita, Shingo
    Okada, Toshiaki
    Gemba, Kenichi
    Fujii, Masanori
    Takigawa, Nagio
    Oda, Naohiro
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1005 - 1009
  • [29] Combining Cytotoxic and Targeted Therapies for Lung Cancer
    Zwitter, Matjaz
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1498 - 1499
  • [30] Inequalities in lung cancer: a world of EGFR
    Carbonnaux, Melodie
    Souquet, Pierre-Jean
    Meert, Anne-Pascale
    Scherpereel, Arnaud
    Peters, Matthew
    Couraud, Sebastien
    EUROPEAN RESPIRATORY JOURNAL, 2016, 47 (05) : 1502 - 1509
12345